Arasani, Sahabi -.

HRN: 12-65-99  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/27/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
12/27/2022
01/03/2023
IV
800mg
Q8
UTI
Waiting Final Action 
12/27/2022
CEFUROXIME 750MG (VIAL)
12/27/2022
01/03/2023
IVTT
750 Mg
Q8
UTI
Waiting Final Action 
12/27/2022
MEBENDAZOLE 100MG/5ML, 60ML SUSPENSION
12/27/2022
01/03/2023
ORAL
5ml
OD
T/c Ascariasis
Waiting Final Action 
12/28/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
12/28/2022
01/04/2023
IVT
1g
8 Hrs
H. Pylori Infection
Waiting Final Action 
12/28/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/28/2022
01/04/2023
IVT
270 Mg
8 Hrs
H. Pylori Infection
Waiting Final Action 
12/29/2022
AMOXICILLIN 250MG/5ML, 60ML SUSPENSION (BOT)
12/29/2022
01/04/2023
PO
5ml
TId
H Pylori Infection
Waiting Final Action 
12/29/2022
CLARITHROMYCIN 125MG/5ML, 60ML SUSPENSION (BOT)
12/29/2022
01/04/2023
PO
4ml
BID
H Pylori Infection
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: